Mirum Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRM research report →
Range $130 – $202
Price Chart
About the company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
- CEO
- Christopher Peetz
- IPO
- 2019
- Employees
- 433
- HQ
- Foster City, CA, US
Get TickerSpark's AI analysis on MIRM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.28B
- P/E
- -6.27
- Fwd P/E
- 50.72
- PEG
- 0.00
- P/S
- 9.30
- P/B
- -115.50
- EV/EBITDA
- -8.24
- Div Yield
- 0.00%
- Gross Margin
- 81.70%
- Op Margin
- -25.35%
- Net Margin
- -134.75%
- ROE
- -734.00%
- ROIC
- -22.79%
Latest fiscal year · YoY change
- Revenue
- $521.31M+54.7%
- Gross Profit
- $420.73M+64.8%
- Op Income
- $-22,136,000
- Net Income
- $-23,363,000+73.4%
- EPS
- $-0.47+74.6%
- OCF Growth
- +440.7%
- FCF Growth
- +488.0%
- 52W High
- $130.00
- 52W Low
- $63.23
- 50D MA
- $88.23
- 200D MA
- $98.18
- Beta
- 0.49
- RSI (14)
- 61
- Avg Volume
- 687.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mirum posted another strong quarter, lifted full-year product sales guidance, and said multiple late-stage catalysts could drive the next phase of growth.· November 3, 2026
- Third-quarter net product sales were $186 million, with LIVMARLI at $133 million and bile acid medicines at $52 million.
- Full-year net product sales guidance was raised to $715 million to $720 million.
- Management highlighted positive clinical updates across the portfolio, including Phase III AZURE-1 for Brelovitug, Phase III EXPAND for LIVMARLI, and the approval and launch of Atebrioz.
- Cash used in operations was approximately $4 million, with cash, cash equivalents and investments of approximately $500 million.
- The company said it expects to be cash flow positive next year and has reduced its 2029 convertible note balance by over 80% after recent financing actions.
Mirum reported third-quarter net product sales of approximately $186 million, up from $133 million in the third quarter last year. LIVMARLI generated $133 million in Q3 sales, including $100 million in the U.S., while bile acid medicines contributed $52 million. Year-to-date net product sales were approximately $522 million, which management said already equals full-year 2025 revenues. The company raised full-year net product sales guidance to $715 million to $720 million. On the cost side, cash contribution margin from the commercial business was in the high 50s percent of sales, cash used in operations was approximately $4 million, and total operating expenses were approximately $245 million, including cost of sales of approximately $28 million, SG&A of approximately $70 million, cash R&D of approximately $94 million, in-process R&D of $13 million, and stock-based compensation, depreciation and amortization of $40 million. Management said cash, cash equivalents and investments were approximately $500 million as of September. It also said R&D on a cash basis was approximately 50% of revenues and should stay at about that pace for two more quarters before declining rapidly; full-year 2027 long-term R&D was described as falling to about 10% of revenue. No EPS figure was stated.
Chris Peetz framed the quarter as another strong period commercially and clinically, saying Mirum is entering its next phase from a position of strength. He emphasized that the company now has four approved medicines, a commercial business approaching $0.75 billion in annual net product sales, and a late-stage pipeline with multiple potential approvals and label expansions ahead. His tone was upbeat and confident, with repeated focus on durability of the business, multiple upcoming catalysts, and the potential for the portfolio to exceed $4 billion in peak revenue.
Eric Bjerkholt said third-quarter performance reflected ongoing top-line growth with disciplined investment in late-stage programs. He cited approximately $186 million in quarterly product sales versus $133 million a year ago, high-50s percent cash contribution margin, and approximately $4 million of cash used in operations. He also detailed the quarter’s spending mix and said the business remains resource-rich, ending September with approximately $500 million in cash, cash equivalents and investments. On capital allocation, he highlighted the September repurchase of $20 million of 2029 convertible notes for about $62 million in cash, following the second-quarter financing that included $690 million of 0% convertible notes due in 2032 and settlement of 75% of the outstanding 2029 notes, reducing the 2029 balance by over 80% and lowering future dilution and interest expense.
Analysts focused on the raised sales outlook, exclusivity risk in the bile acid franchise, the timing of PSC filing, Atebrioz’s early launch, the upcoming VANTAGE readout, and whether the company has the bandwidth for multiple 2027 submissions and business development. Management said the guidance increase was driven mainly by adult PFIC growth, with LIVMARLI showing continued strength in Alagille syndrome and bile acid products also contributing. On exclusivity, management said CHOLBAM is beyond orphan exclusivity, CTEXLI has orphan protection, and they have not seen an entrant. On PSC, they reiterated confidence in a first-half-2027 NDA submission, said FDA interactions are meant to increase familiarity rather than achieve full alignment, and noted the recent PSC IBD analyses are new and were not previously seen by FDA. For Atebrioz, management described the early launch as very positive with strong receptivity but said it is still early days. On VANTAGE, they declined to discuss baseline details but said the interim volixibat data, including over a 2-point placebo-adjusted improvement, make them confident going into next quarter’s readout.
The call pointed to multiple visible growth drivers: stronger-than-expected commercial sales, an expanding fourth product with Atebrioz, and several near-term clinical/regulatory catalysts. Management sounded confident that adult PFIC, continued LIVMARLI adoption, and future launches can sustain revenue growth into 2027 and beyond. They also expressed optimism that the balance sheet and recent refinancing leave them well-positioned for launches and development work.
The biggest risks discussed were regulatory and execution-related: multiple important filings are concentrated in the first half of 2027, and the company is still navigating PSC interactions with FDA. Management also noted that some R&D and manufacturing spending will remain elevated for about two more quarters, and the HDV and PSC opportunities still depend on future data and submissions. On the commercial side, Atebrioz is only just launched, and the bile acid franchise still carries some exclusivity and potential competition questions, even though no entrant has been seen so far.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.8%
- Shares Outstanding
- 65.28M
- Float Shares
- 54.08M
of shares held by institutions
340 13F filers
Buy/sell ratio 0.80. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.68M | 0 |
| Janus Henderson Group Ltd. | 6.95M | ▲ 880.50K |
| Jupiter Topco LLC | 5.91M | ▲ 5.91M |
| Blackrock, Inc. | 4.39M | ▲ 543.53K |
| Fmr LLC | 4.07M | ▲ 403.44K |
| Price T Rowe Associates Inc | 2.66M | ▲ 938.19K |
| Vanguard Group Inc | 2.60M | ▲ 50.72K |
| State Street Corp | 2.39M | ▲ 219.99K |
| Vanguard Portfolio Management LLC | 2.38M | ▲ 944.94K |
| Vanguard Capital Management LLC | 2.25M | ▼ 160.67K |
| Invesco Ltd. | 1.53M | ▲ 170.42K |
| Geode Capital Management, LLC | 1.45M | ▲ 56.81K |
Held by 386 ETFs
Biggest fund positions in MIRM by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Ramasastry Saira | other | 2,000 |
| Nov 16, 26 | Ramasastry Saira | other | 2,000 |
| Nov 16, 26 | Ramasastry Saira | sell | 2,000 |
| Nov 11, 26 | Brege Laura | other | 14,167 |
| Nov 11, 26 | Brege Laura | sell | 10,907 |
| Nov 11, 26 | Brege Laura | sell | 3,260 |
| Nov 11, 26 | Brege Laura | other | 14,167 |
| Nov 4, 26 | Peetz Christopher | other | 20,000 |
| Nov 4, 26 | Peetz Christopher | sell | 20,000 |
| Nov 4, 26 | Peetz Christopher | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MIRM coverage
Recent articles, reports, and earnings notes.
Want a deeper read on MIRM?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 15
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 12
MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV
zacks.com · Nov 11
Mirum's liver infection drug lowers virus levels in second late-stage study
reuters.com · Nov 10
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
businesswire.com · Nov 10
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock
defenseworld.net · Nov 7
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $1,800,000.00 in Stock
defenseworld.net · Nov 7
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
businesswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
